JT
PTGX icon

Jump Trading’s Protagonist Therapeutics PTGX Stock Holding History

Jump Trading’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12,624
Closed -$159K – 529
2019
Q1 		$159K Buy
+12,624
New +$111K 0.05% 432
2018
Q3 		– Sell
-13,847
Closed -$93K – 546
2018
Q2 		$93K Buy
+13,847
New +$106K 0.01% 332

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Jump Trading's PTGX Position: Q2 2019 in Review

Jump Trading sold out of Protagonist Therapeutics (PTGX) in Q2 2019, closing a stake of 12,624 shares — an estimated $159K sold.

Jump Trading first reported a position in PTGX in Q2 2018 and held it in 2 quarters. The position peaked at $159K in Q1 2019. 66 funds tracked by Wall St. Rank hold PTGX as of Q2 2019.

  • Jump Trading reported no remaining Protagonist Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Jump Trading sold 12,624 Protagonist Therapeutics shares in Q2 2019, an estimated $159K.
  • Jump Trading first reported a position in Protagonist Therapeutics in Q2 2018 and held it in 2 quarters.
  • Jump Trading's Protagonist Therapeutics position peaked at $159K in Q1 2019.
  • 66 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2019.

Based on Jump Trading's 13F filing for Q2 2019, filed 14 Aug 2019.